Horizon Pharma Moving Ahead of FDA Decision
(Thomson Reuters ONE) -
By Brian Wilson, Contributor
Shares of the pain drug developer Horizon Pharma (NASDAQ:HZNP) have recently
seen some huge moves to the upside as the FDA's decision looms for the company's
rheumatoid arthritis treatment RAYOS gets closer. Even after a virtual doubling
of the shares since June, the company is valued at modest $265 million.
The two major firms that cover the stock (Stifel Nicolaus and JMP Securities)
have price targets that exceed the current price of $7.12/share by significant
margins. According to an article by Bret Jensen of Seeking Alpha, Stifel
Nicolaus has a target of $10/share while JMP sees $16/share. These price targets
imply 40% and 125% upsides respectively.
In addition to bullishness from analysts, insider buying has warranted some
investor attention to the stock as well. Although it wasn't recent, we saw a
huge round of buying in early March by directors Jeffery Bird, Jeff Himawan (of
Essex Woodlands), and Jean Francois (of Atlas Venture). The buying spree brought
4.4 million shares out of the market, which is quite enormous given the small
number of shares floated (at 33.7 million).
Despite steep operating losses, investors are noting the huge potential value of
the rheumatoid arthritis RAYOS in the ~$11 billion market for prescription pain
medication and the huge revenue growth potential for the osteoarthritis and
rheumatoid arthritis drug DUEXIS. DUEXIS only brought in $1.1 of revenue in Q1
2012 but this is expected to explode higher in coming years (the real question
is whether or not it would be enough to offset the operating losses). There are
also two preclinical-stage compounds that the market will largely ignore until
they move on to clinical trials.
Some are saying that RAYOS lacks blockbuster potential since it's merely a
reformulation of low dose prednisone that can only satisfy a niche market. In
addition, Horizon lacks the marketing rights for this drug in Europe which cuts
its peak revenue potential quite drastically. The question of market potential
can be asked of DUEXIS, (ibuprofen/famotidine), which is another reformulation
compound that will struggle against drugs that already dominate the
osteoarthritis/rheumatoid arthritis market.
Until July 26, 2012 I expect that both sides of the market will induce some
volatility as the players (primarily institutions) place their last bets on the
table before the FDA decision. The question of whether or not RAYOS and DUEXIS
will be able to penetrate the market sufficiently to meet analyst expectations
will surely return later on.
To recap, HZNP is a purely speculative trade until the PDUFA action date of July
26(th). After the approval (or rejection), it will be a matter of evaluating
DUEXIS (and potentially RAYOS) for their rate of sales growth and peak
potential. Remember that Horizon is operating at steep losses, and needs to
market DUEXIS effectively to justify its current market capitalization. Insider
buying and analyst targets suggest huge under appreciation of RAYOS/DUEXIS,
although these ought to be taken with a grain of salt.
The complete report on Horizon Pharma is available at:
http://www.biomedreports.com/20120720100340/horizon-pharma-moving-ahead-of-fda-
decision.html
Healthcare investors and Biotech traders interested in accessing BioMedReports'
new complete database of clinical trials and upcoming FDA and world-wide
regulatory decisions which can be used to make more profitable trades and see
upcoming catalysts can go to: http://biomedreports.com/fdacal.html
Follow Us
News developments and live healthcare sector updates are available constantly
via twitter at: http://twitter.com/BioMedReports
####
About BioMedReports.Com
BioMedReports is a news and research portal covering financial biomedical news
and the entire Healthcare Sector of the market. BioMedReports is not paid or
compensated to report the news and developments of publicly traded companies.
BioMedReports sells a premium product for subscribers and full disclosures and
information about the stocks and news mentioned in this news release is
available at BioMedReports.Com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: BioMedReports via Thomson Reuters ONE
[HUG#1628336]
Datum: 20.07.2012 - 14:51 Uhr
Sprache: Deutsch
News-ID 167275
Anzahl Zeichen: 5135
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 512 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Horizon Pharma Moving Ahead of FDA Decision"
steht unter der journalistisch-redaktionellen Verantwortung von
BioMedReports (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
